back to Australia directory
australia clinical guidance

Osteoporosis (fragility fracture risk assessment + pragmatic treatment pathways)

A detailed Australian summary of osteoporosis (fragility fracture risk assessment + pragmatic treatment pathways), with source-attributed priorities, a practical workflow, safety escalation and state or territory implementation boundaries.

JurisdictionAustralia
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Australia
This is an iatroX educational summary of named Australia sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Apply current TGA product information, PBS restrictions, state or territory law, local referral criteria, formulary and antimicrobial policy. A national recommendation does not create uniform service access.

Scope

Treat a minimal-trauma fracture as a sentinel event and assess future fracture risk, falls, secondary causes, calcium intake and vitamin D status. Use bone density and an Australian-supported fracture-risk tool when the result will alter treatment, recognising that some fractures establish high risk without it. This summary is limited to the population, decisions and escalation boundaries stated in the named source.
sources for this section:RACGP/Healthy Bones osteoporosis

The Bottom Line

  • Treat a minimal-trauma fracture as a sentinel event and assess future fracture risk, falls, secondary causes, calcium intake and vitamin D status.
  • Use bone density and an Australian-supported fracture-risk tool when the result will alter treatment, recognising that some fractures establish high risk without it.
  • Investigate vertebral fracture when height loss or kyphosis is present because many fractures are clinically silent.
  • Choose anti-osteoporosis therapy by fracture risk, kidney function, oral tolerance, adherence, dental considerations and capacity for long-term sequencing.
sources for this section:RACGP/Healthy Bones osteoporosis

Practical clinical workflow

1

Topic-specific assessment action

Treat a minimal-trauma fracture as a sentinel event and assess future fracture risk, falls, secondary causes, calcium intake and vitamin D status.
2

Topic-specific diagnostic action

Choose anti-osteoporosis therapy by fracture risk, kidney function, oral tolerance, adherence, dental considerations and capacity for long-term sequencing.
3

Topic-specific management action

Plan duration and transition before denosumab or other potent therapy is stopped, because unplanned cessation can cause rapid bone loss and vertebral fractures.
4

Topic-specific follow-through

Oral bisphosphonate needs safe swallowing and administration capability; intravenous therapy has separate kidney and acute-reaction considerations.
sources for this section:RACGP/Healthy Bones osteoporosis

Safety boundaries and escalation

  • New severe back pain, height loss or neurological symptoms may indicate vertebral fracture; hip fracture and acute cord compromise require urgent assessment.
  • Falls exercise, vision and medicine review remain necessary even when pharmacological bone treatment is started.
sources for this section:RACGP/Healthy Bones osteoporosis

Implementation

The named source is national or binational guidance used in Australia, but referral access, public-health directions, formularies and funded services can still differ by state, territory and health service. Check current TGA product information for medicines. Offer culturally safe care and use the NACCHO鈥揜ACGP National Guide where Aboriginal and Torres Strait Islander preventive or chronic-care recommendations differ.
sources for this section:RACGP/Healthy Bones osteoporosis

Clinical use boundary

This independently written summary is not an official guideline. Check the linked source version, current TGA-approved product information where medicines are involved, and the applicable state, territory and local pathway at the point of care.

sources for this section:RACGP/Healthy Bones osteoporosis

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Royal Australian College of General Practitioners and Healthy Bones AustraliaOsteoporosis management and fracture prevention in postmenopausal women and men over 50 years of age3rd edition, March 2024 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Australia question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.